Recent News

• 10.30.2026 - Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities
• 10.28.2026 - Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast
• 09.04.2026 - Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems
• 08.24.2026 - AZENTA ANNOUNCES LEADERSHIP TRANSITION
• 08.04.2026 - Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
• 07.22.2026 - Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
• 07.14.2026 - Beyond the Freezing Point: The Science of Biopharmaceutical Preservation
• 07.08.2026 - Azenta Completes Sale of B Medical Systems
• 07.01.2026 - Lab Chemical Relocation: Hidden Risks and How to Avoid Them
• 06.10.2026 - Why Biological Material Lab Relocation Requires Much More Than Boxes and a Moving Truck

Recent Filings

• 10.30.2026 - 8-K Current report
• 10.30.2026 - EX-99.1 EX-99.1
• 10.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2026 - 8-K Current report
• 09.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2026 - 8-K Current report
• 09.17.2026 - EX-99.1 EX-99.1
• 09.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.16.2026 - 4 Statement of changes in beneficial ownership of securities